What started as IDC (Infiltrating Ductal Carcinoma) in 2011, then turned into CHF (Congestive Heart Failure) in 2013, probably partially caused by chemotherapy along with a genetic pre-disposition. Here we are now in March 2016 and I am newly diagnosed with Stage IV breast cancer in the left breast and liver (LMBC - liver metastasized breast cancer).

So the focus has shifted yet again, BUT... I continue to THANK YOU for your prayers, love & support. I receive them with open & loving arms. My wish is that I will gain strength from you, will provide helpful information and strength to others & will help to strip away the fears we each experience.

I am strong. I am loved. I am healthy. I WILL SURVIVE!

Have you or your loved one had their annual mammogram? PLEASE, don't put it off. Speaking from experience, I highly recommend monthly self exam as well. And if you are now cancer free of breast cancer, do everything you can to insist that your doctors follow up with an occasional PET Scan and labs for tumor markers.

Contents may be uplifting, sad, funny, scary, downright depressing ~ THAT IS CANCER .... at it's best, at its worst.

PLEASE ~ Feel free to share this blog with anyone who is interested to learn about my journey. While I welcome their support, I hope that by sharing this experience freely to the universe I may help to support others by breaking down some of the barriers and fear associated with breast cancer and the treatment.


Monday, February 29, 2016

PSTx Dedicated to Development of High Impact & Affordable Cancer Treatment

Paradigm Shift Therapeutics (PSTx) was launched in January 2014 by Teresa Burgess, PhD and Kate Farrell, PhD through an ongoing collaboration with Dr. David Roberts at the National Cancer Institute (NCI) focused on developing CD47-targeting inhibitors-a novel immune-checkpoint target with the potential to radically change treatment for cancer patients.  Thomas Miller PhD joined PSTx as a full partner in September 2014. PSTx's public-private partnership with the National Institutes of Health (NIH) was expanded in September 2015 to launch a drug screening program with the National Center for Accelerating Translational Sciences (NCATS).

PSTx is grateful for ongoing funding from the Avon Foundation for Women and for the business development support from BioHealth Innovation.

While that may sound like a bunch of science jargon that is hard to get your mind wrapped around, you just need to know that PSTx is dedicated to the development of high impact and affordable cancer therapies.

Breast Cancer Stakeholders:  YOUR OPINION MATTERS!
Please help PSTx to develop better cancer therapies that maximize patient benefits by participating in a simple survey. Contact Cameron or Sebastian at the email addresses below to set up a quick phone interview.

I did, and I'm glad I did.

Here's to our health...

Life is Good...

Debbie... aka the cancer SURVIVOR, 
AND now the Cardiomyopathy warrior!!!

THANKS for visiting! Comments are good. I look forward to your comments.

No comments:

Post a Comment

Thank you for visiting and leaving a comment. Your comment will be reviewed and approved the next time I visit.